<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7707449</journal-id>
<journal-id journal-id-type="pubmed-jr-id">656</journal-id>
<journal-id journal-id-type="nlm-ta">Ann Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann. Neurol.</journal-id>
<journal-title-group>
<journal-title>Annals of neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0364-5134</issn>
<issn pub-type="epub">1531-8249</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29331082</article-id>
<article-id pub-id-type="pmc">5821556</article-id>
<article-id pub-id-type="doi">10.1002/ana.25149</article-id>
<article-id pub-id-type="manuscript">NIHMS934059</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Talos</surname>
<given-names>Delia M.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jacobs</surname>
<given-names>Leah M.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gourmaud</surname>
<given-names>Sarah</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Coto</surname>
<given-names>Carlos A</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Hongyu</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lim</surname>
<given-names>Kuei-Cheng</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lucas</surname>
<given-names>Timothy H.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Davis</surname>
<given-names>Kathryn A.</given-names>
</name>
<degrees>MD, MS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Lage</surname>
<given-names>Maria</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN2">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jensen</surname>
<given-names>Frances E.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States</aff>
<aff id="A2">
<label>2</label>Department of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States</aff>
<aff id="A3">
<label>3</label>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States</aff>
<aff id="A4">
<label>4</label>Department of Neuroscience, Carleton University, Ottawa, ON, Canada</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author: Delia M. Talos, MD, 415 Curie Boulevard, 263 Clinical Research Building, Philadelphia, PA 19104, phone and fax: 215-573-8328 (phone); 215-662-3362 (fax), <email>talosd@pennmedicine.upenn.edu</email></corresp>
<fn fn-type="equal" id="FN2">
<label>#</label>
<p>These authors contributed equally to this work.</p>
</fn>
<fn fn-type="COI-statement" id="FN4">
<p>POTENTIAL CONFLICT OF INTEREST</p>
<p>None of the authors has any conflict of interest to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>2</month>
<year>2019</year>
</pub-date>
<volume>83</volume>
<issue>2</issue>
<fpage>311</fpage>
<lpage>327</lpage>
<!--elocation-id from pubmed: 10.1002/ana.25149-->
<abstract>
<sec id="S1">
<title>Objective</title>
<p id="P1">Temporal lobe epilepsy (TLE) is a chronic epilepsy syndrome defined by seizures and progressive neurological disabilities, including cognitive impairments, anxiety and depression. Here, human TLE specimens were investigated focusing on the mechanistic target of rapamycin (mTOR) Complex 1 (mTORC1) and Complex 2 (mTORC2) activities in the brain, as both pathways may represent unique targets for treatment.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">Surgically resected hippocampal and temporal lobe samples from therapy-resistant TLE patients were analyzed by Western blotting to quantify the expression of established mTORC1 and mTORC2 activity markers and upstream or downstream signaling pathways involving the two complexes. Histological and immunohistochemical techniques were used to assess hippocampal and neocortical structural abnormalities and cell-specific expression of individual biomarkers. Samples from patients with focal cortical dysplasia (FCD) type II served as positive controls.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">We found significantly increased expression of phospho-mTOR (Ser2448), phospho-S6 (Ser235/236), phospho-S6 (Ser240/244) and phospho-Akt (Ser473) in TLE samples compared to controls, consistent with activation of both mTORC1 and mTORC2. Our work identified the PI3K and Ras/ERK signaling pathways as potential mTORC1 and mTORC2 upstream activators. In addition, we found that overactive mTORC2 signaling was accompanied by induction of two Akt-dependent pro-survival pathways, as evidenced by increased inhibitory phosphorylation of FoxO3a (Ser253) and GSK-3Î² (Ser9).</p>
</sec>
<sec id="S4">
<title>Interpretation</title>
<p id="P4">Our data demonstrate that mTOR signaling is significantly dysregulated in human TLE, offering new targets for pharmacologic interventions. Specifically, clinically available drugs that suppress mTORC1 without compromising mTOR2 signaling, such as rapamycin and its analogs, may represent a new group of antiepileptogenic agents in TLE patients.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>